Novel approaches to plant drug discovery based on high throughput pharmacological screening and genetic manipulation

被引:28
|
作者
Littleton, J
Rogers, T
Falcone, D
机构
[1] Univ Kentucky, KTRDC, Lexington, KY 40546 USA
[2] Univ Massachusetts, Dept Biol Sci, Lowell, MA 01854 USA
关键词
drug discovery; plants; nicotinic acetylcholine receptors; radioligand binding; NICOTINIC ACETYLCHOLINE-RECEPTORS; ALPHA-BUNGAROTOXIN; ALZHEIMERS-DISEASE; BINDING-SITES; RAT-BRAIN; NEUROPROTECTION; (-)-NICOTINE;
D O I
10.1016/j.lfs.2005.09.013
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Plants are potentially important for novel therapeutic drug leads, but the slowness of conventional methods for investigation of plants limits enthusiasm in the pharmaceutical industry. To overcome some of the drawbacks, we have applied high throughput pharmacological screening (HTPS) to crude plant extracts. Using a "differential smart screen", (DSS) the spectrum of activity contained in a crude extract is measured at several closely related receptor subtypes. This spectrum is then compared to that of known compounds. A unique spectrum suggests that the extract merits further investigation. Evaluation of species and environmental libraries of whole plants has demonstrated the value of this approach for rapid prioritization of plants for investigation. In addition, genomic and genetic manipulation of plants and plant cell cultures can increase the value of DSS. For example, the whole genomic potential of a plant species for biodiversity can be accessed by using gain of function mutations to generate a "functional genomics library" of mutant clonal cultures, and the bioactivity of these cultures tested by DSS. Clones that overproduce activity differing from the wild-type plant can be identified in this way. This "Natural Products Genomics" (NPG) strategy is limited by the massive numbers of clonal cultures that are required to cover all possible gain-of-function mutations. The rapidity and efficiency of this process can be improved by using transgenic plants expressing appropriate mammalian proteins. These may be designed to make the plant cell resemble a human cell for a specific form of toxicity. Now, "unnatural selection" of resistant mutant clones can be used to provide a sub-population potentially enriched in useful compounds. Alternatively, transgenic plant cells can be used for "in situ screening" in which a mammalian receptor protein, linked to a reporter construct, such as green fluorescent protein, is expressed. Clonal cultures that produce ligands for this receptor can now be rapidly identified visually in an ultra-HTPS. Overall, our aim is to use pharmacological screening, together with functional genomic approaches, to make plant drug discovery competitive with combinatorial chemistry. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:467 / 475
页数:9
相关论文
共 50 条
  • [41] A High-Throughput Screen for Antibiotic Drug Discovery
    Scanlon, Thomas C.
    Dostal, Sarah M.
    Griswold, Karl E.
    BIOTECHNOLOGY AND BIOENGINEERING, 2014, 111 (02) : 232 - 243
  • [42] High throughput drug discovery with ESI-FTICR
    Sannes-Lowery, KA
    Cummins, LL
    Chen, S
    Drader, JJ
    Hofstadler, SA
    INTERNATIONAL JOURNAL OF MASS SPECTROMETRY, 2004, 238 (02) : 197 - 206
  • [43] High-throughput and in silico screenings in drug discovery
    Phatak, Sharangdhar S.
    Stephan, Clifford C.
    Cavasotto, Claudio N.
    EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (09) : 947 - 959
  • [44] Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
    Bajusz, David
    Ferenczy, Gyorgy G.
    Keseru, Gyorgy M.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2017, 17 (20) : 2235 - 2259
  • [45] Discovery of Novel PTP1B Inhibitors by High-throughput Virtual Screening
    Debnath, Abhijit
    Rani, Anjna
    Mazumder, Rupa
    Mazumder, Avijit
    Singh, Rajesh Kumar
    Sharma, Shalini
    Srivastava, Shikha
    Chaudhary, Hema
    Mishra, Rashmi
    Khurana, Navneet
    Sanchitra, Jahanvi
    Jan, Sk Ashif
    CURRENT COMPUTER-AIDED DRUG DESIGN, 2024,
  • [46] Discovery of novel TAOK2 inhibitor scaffolds from high-throughput screening
    Piala, Alexander T.
    Akella, Radha
    Potts, Malia B.
    Dudics-Giagnocavo, Stephanie A.
    He, Haixia
    Wei, Shuguang
    White, Michael A.
    Posner, Bruce A.
    Goldsmith, Elizabeth J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (16) : 3923 - 3927
  • [47] High-throughput flow cytometric screening of combinatorial chemistry bead libraries for proteomics and drug discovery
    Leary, JF
    Reece, LM
    Yang, XB
    Gorenstein, D
    Advanced Biomedical and Clinical Diagnostic Systems III, 2005, 5692 : 216 - 223
  • [48] Drug discovery for male subfertility using high-throughput screening: a new approach to an unsolved problem
    da Silva, Sarah J. Martins
    Brown, Sean G.
    Sutton, Keith
    King, Louise V.
    Ruso, Halil
    Gray, David W.
    Wyatt, Paul G.
    Kelly, Mark C.
    Barratt, Christopher L. R.
    Hope, Anthony G.
    HUMAN REPRODUCTION, 2017, 32 (05) : 974 - 984
  • [49] A Fully Automated High-Throughput Flow Cytometry Screening System Enabling Phenotypic Drug Discovery
    Joslin, John
    Gilligan, James
    Anderson, Paul
    Garcia, Catherine
    Sharif, Orzala
    Hampton, Janice
    Cohen, Steven
    King, Miranda
    Zhou, Bin
    Jiang, Shumei
    Trussell, Christopher
    Dunn, Robert
    Fathman, John W.
    Snead, Jennifer L.
    Boitano, Anthony E.
    Nguyen, Tommy
    Conner, Michael
    Cooke, Mike
    Harris, Jennifer
    Ainscow, Ed
    Zhou, Yingyao
    Shaw, Chris
    Sipes, Dan
    Mainquist, James
    Lesley, Scott
    SLAS DISCOVERY, 2018, 23 (07) : 697 - 707
  • [50] Toward high-throughput drug screening on a chip-based parallel affinity separation platform
    Ohlson, Sten
    Duong-Thi, Minh-Dao
    Bergstrom, Maria
    Fex, Tomas
    Hansson, Lennart
    Pedersen, Lennart
    Guazotti, Sergio
    Isaksson, Roland
    JOURNAL OF SEPARATION SCIENCE, 2010, 33 (17-18) : 2575 - 2581